chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Dizziness and malaise- intermittent starting 3 hours after the shot. Also, my head didn't feel right. The next morning at about 9am- fatigue, dizziness and foggy thinking. Dizziness continues intermittently (1/12/2021)
Left arm has red itchy mark about the size of a silver dollar where shot was; Left arm has red itchy mark about the size of a silver dollar where shot was; This is a spontaneous report from a contactable consumer, the patient. This 34-year-old female patient received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine) (Lot number: EL0142), dose number 1, via an unspecified route of administration in the left arm on 07Jan2021 at 11:30 (at the age of 34-years-old) as a single dose for COVID-19 vaccination. Medical history included asthma from an unknown date and unknown if ongoing, depression from an unknown date and unknown if ongoing, sulfa allergy from an unknown date and unknown if ongoing and penicillin allergy from an unknown date and unknown if ongoing. Concomitant medication included sertraline hydrochloride (ZOLOFT), unspecified birth control and salbutamol sulfate (ALBUTEROL [SALBUTAMOL SULFATE]). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient was not pregnant at the time of vaccination. On 21Jan2021 at 10:00, the patient experienced her left arm has a red, itchy mark about the size of a silver dollar where the shot was. No therapeutic measures were taken as a result of the events. The clinical outcomes of her left arm has a red, itchy mark about the size of a silver dollar where the shot was not resolved. It was also reported that since the vaccination, the patient had not been tested for COVID-19.
Patient stopped by the pharmacy, on 7/30/21 at around noon, informing me that he  had a seizure after the vaccine. The patient received the immunization on 7/22/21 (Thursday). The patient was advised to stay for monitoring for 15 minutes but left the scene due to a cab waiting for him. Per the patient he did not feel anything at that time. Later on in the day he started feeling nauseated, that nausea has come and gone since he received the immunization. He stated that on Sunday night (7/25) he experienced a seizure; since he felt his ribs hurting, he also bit his cheek and lip, per the patient "he knows when he has a seizure". Patient also stated he has not had an appetite since he received the vaccine and has not been able to eat normally. The patient lives alone and no one could confirm the seizure.   The patient does take seizure medications and per the patient his seizures have been controlled at the time of vaccination. The patient was advised to speak to the doctor regarding receiving the second dose. At this time, I advised the patient to not proceed with the second dose until he speaks with his primary care provider.   I informed the patient how unusual it is to experience side effects and informed him I would file a report regarding our conversation. He would like someone to reach out to him to speak to him about the situation- I informed him that I would submit a report to VAERS with a request to reach out to him. In the meantime I advised him to reach out to his doctor. The immunizing pharmacist. Nothing further to report at this time.
Patient had a raised lump at the injection site along with redness, itching, it also was inflamed
2nd dose of Pfizer was administered 14 days after 1st dose. Patient had 1st dose completed at another clinic site and did not have her vaccination card with her at time seen in our clinic.
Lips got swollen and "itchy" and "tingles"; felt a little "dizzy".
Initial misuse report received from a healthcare professional on 09 April 2013. ADACEL was given to a 4-year-old patient (No more information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none.
patient got ill, vomit and sickness - no local reaction -severe sickness she describes went to urgent care vitals were not good she stated and went to hospital- stable today doing better - on prednisone
rash behind both knees; This case was reported by a consumer via call center representative and described the occurrence of rash in a 79-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 21st July 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 22nd July 2020, 1 days after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was not recovered/not resolved.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were reported as follows: The patient received Shingrix in left arm and developed a rash behind both knees. The reporter was unable to provide lot number and expiration date and gives consent to follow up with patient's physician. The reporter consented to follow up.
This spontaneous report as received from a registered nurse refers to a 15 years old female patient without pertinent medical history. The patient was vaccinated with intramuscular GARDASIL (lot # 672653/1860AA, expiration date 30-SEP-2012, 0.5 ml suspension/0,2 and 6 months). No other co-suspects were reported. Concomitant medications included hepatitis B virus vaccine (unspecified), ADACEL and MENACTRA. On 09-APR-2012 the patient who had received an injection of GARDASIL "had syncopy". No treatment was given for adverse event. The outcome of syncope was unknown. The patient did not seek medical attention. Additional information has been requested.
Breakthrough COVID infection in fully vaccinated patient. Positive date 10/22/2021.
Patient hospitalized overnight for afebrile seizure. Normal head CT and EEG. Released with no meds.
Began crying as soon as left office & cried high pitch cry for 5 hrs non stop;
Nausea; Confusion; Fatigue; Lightheaded/ dizziness; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3184) via an unspecified route of administration in the left arm on 27Aug2021 at 17:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety, depression, peripheral neuropathy, fatigue and penicillin allergy. It was unknown whether the patient was diagnosed with COVID-19 prior to the vaccination. Concomitant medications included unspecified medications for an unknown indication from on an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: PA7485) via an unspecified route of administration in the left arm on 06Aug2021 at 17:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. On 28Aug2021 at 16:00 the patient experienced nausea, confusion, fatigue, lightheadedness and dizziness. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events nausea, confusion, fatigue, lightheadedness and dizziness were not recovered at the time of this report.
At roughly 5:30 AM I was awoken by violent muscle tremors that did not subside for several minutes. The problem was resolved on its own but the experience was extremely uncomfortable.
Patient was waiting after vaccination in a car with another family member, The family member alerted staff that patient did not feel well. Nurse immediately assessed the patient and found the following signs of adverse event: garbled stuttered speech, right arm limp, staring in one direction. Nurse alerted another staff member to call 911. Second nurse arrived to car with Epi Pen and administered the Epi Pen. Immediately, the patient's symptoms resolved and she said that she felt better. Patient was transported via EMS to hospital as a precaution. At the time the patient left the vaccination facility, she no longer had any symptoms.
Patient received 0.2ml of Pfizer Adult Ready to Use vaccine intramuscularly into left deltoid at 5:40 PM 01/21/2022 rather than 0.2ml of Pfizer Pediatric vaccine.
Redness, swelling & very warm to touch, about 2 " in diameter. Began immediately & lasted 3-4 wks w/less severity. Muscles in arm & chest sore for 1 1/2 wks, gradually disappearing. Dr said adverse reacton/infection.
Presented with SOB; flu-like symptoms, cough x2-3 days; CXR: right basiliar opacity suspicious for PNA; dx NSTEMI and Covid + PNA; Tx: Decadron, heparin, remdesivir, Vit C, Zinc; Initially on HFO2, down to 4 LPM O2 @ d/c
Information has been received from a published article, concerning a 14 year old patient who in October 2008, was vaccinated with MMR II (lot # not reported) at school. Between 20-OCT-2008 and 23-OCT-2008, the patient experienced weakness, periodic hot flashes, dizziness and anxiety attacks. The events required a particularly exaggerated health care response including 15 days in three different hospitals, a variety of diagnoses, and treatment with intravenous fluids, parenteral and oral steroids, antihistamines, vitamins and diuretics. Despite the scarcity of objective findings, the staff at the regional hospital perceived the patient as seriously ill because of persistent complaints (primarily of weakness, periodic hot flashes and dizziness). Based on review of clinical information from AEFI (adverse events following immunization) reports the patient had signs and symptoms compatible with anxiety attacks with subsequent relapses. The outcome of the events was not reported. The authors considered that weakness, periodic hot flashes, dizziness and anxiety attacks were linked to the immunization sessions held at school. This is one of several reports received from the same source. Additional information has been requested. A copy of the published article is attached as further documentation of the patient's experience.
Localized reaction on right thigh. Injection site red, swollen (10 cm), warm to touch. Reaction noticed evening of 1/9/13. No treatment required.
DTP given AM 13FEB91; no rxn until evening 14FEB91, pt developed swelling & macular flush @ inject site. Next AM, pt seemed normal @ 8AM developed difficulty walking w/mild ataxia. PE showed mild ataxia,otherwise WNL. Dx = mild cerebellitis
Cancer; Shingles; This is a spontaneous report from a contactable consumer (patient). A 75-year-old male patient received the first and second doses of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot number and expiration date were not reported) as a single dose, with route of administration and therapy dates unspecified, for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient had cancer and shingles. The patient had developed the shingles due to the chemotherapy (for the cancer). The patient got the shingles after the first dose, and around the time of the second (but was not sure it before or after). The patient was also on radiation therapy for cancer and valaciclovir (VALTREX) for the shingles. The outcome of the events, cancer and shingles, was unknown.  Information on the batch/lot number has been requested.
Hand shake; Headache; Muscle pain; Nausea; Chills; Low grade fever; This spontaneous case was reported by a consumer and describes the occurrence of TREMOR (Hand shake), HEADACHE (Headache), MYALGIA (Muscle pain), NAUSEA (Nausea) and CHILLS (Chills) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No medical history reported.).    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Jan-2021, the patient experienced TREMOR (Hand shake), HEADACHE (Headache), MYALGIA (Muscle pain), NAUSEA (Nausea), CHILLS (Chills) and PYREXIA (Low grade fever). At the time of the report, TREMOR (Hand shake), HEADACHE (Headache), MYALGIA (Muscle pain), NAUSEA (Nausea), CHILLS (Chills) and PYREXIA (Low grade fever) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
This spontaneous report as received from a physician refers to a 12 years old male patient. The patient was vaccinated with the first dose GARDASIL (lot number and expired date were not reported) (0.5 ml/3 shot series intramuscular injection) on 25-JUL-2011. No other co-suspects were reported. No concomitant medications were reported. The second shot of GARDASIL was given on 30-SEP-2011 and the third shot was given on 01-DEC-2011. The patient received his third dose of GARDASIL too early. No adverse reaction was reported. The outcome was unknown at the time of report. It was unspecified if the patient had sought medical attention. Additional information has been requested.
This spontaneous report was received from a healthcare worker via a company representative, referring to two unspecified patients of unknown age and gender. Concurrent conditions or pertinent medical history were not reported. It was reported that on an unspecified date, the patients were vaccinated with a dose of (Merck) VARIVAX solution for injection (does, route of administration and frequency were not reported). Later on an unknown date, the patients received a second dose of (Merck) VARIVAX solution for injection (dose, route of administration and frequency were not reported). The healthcare worker stated that (Merck) VARIVAX "did not work after a couple of years" (vaccination failure) because these two patients who received the vaccine "got the disease". It was reported that this occurred recently on an unspecified date within this past year, approximately in 2014. At the time of the report, the outcome of adverse event and vaccination failure was unknown. The relatedness of (Merck) VARIVAX with the varicella and vaccination failure was not reported. Additional information has been requested.
Left arm numbness, tingling immediately after vaccine. Feeling like she had swallowed something big about 15 minutes later. 30 minutes later severe headache  (10/10), nausea, lightheadedness.  10:30 AM The patient took 400mg Motrin and then about 1 1/2 hours later 500mg Excedrin. She was able to eat lunch without difficulty. No chest pain, shortness of breath, trouble swallowing, vision changes, weakness, or decreased movement of her extremities. No loss of balance.  She states the sensation in her throat has subsided.  01:30 PM Now the headache is a 4/10. Minimally lightheaded. No nausea. No chest pain or shortness of breath. Feels like she can do her work. Her arm numbness is going away. Stable on exam. No further medications. Functions well.
Nausea; Vomiting; Chills; Fever; Headache; Muscle aches; This is a spontaneous report from a non-contactable other health care professional. A 58-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via unspecified route administered in left arm on 17Mar2021 at 14:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, low thyroid and breast cancer. The patient was allergic to penicillin and levaquin. Concomitant medications included lisinopril (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), letrozole (MANUFACTURER UNKNOWN), low-dose aspirin ((MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247), via unspecified route administered in left arm on 23Feb2021 at 15:00 as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Mar2021, approximately 24 hours after receiving the vaccination, the patient experienced nausea, vomiting, chills, fever, headache and muscle aches. All events began to subside within 18 hours but still present. Therapeutic measures were taken as a result of nausea, vomiting, chills, fever, headache and muscle aches and included treatment with water, ibuprofen and rest. The clinical outcome of the events nausea, vomiting, chills, fever, headache and muscle aches were resolving.   No follow-up attempts are needed. No further information is expected.
about 18hrs. after shot (L) arm became red & swollen, & sore (normal w/shot pain) (nothing serious) went from deltoid to elbow - only on inside of arm was red & swollen. Patient took advil and rash was clear within 2 days.
Information has been received from physician concerning a 30 year old female who on approximately 12JUN2001 was vaccinated was vaccinated with rubella virus vaccine live (second generation). Subsequently, a rubella titer did not show seroconversion. Additional information has been requested.
Left arm from injection site to hand is swollen. Injection site became bright red, ball like, skin texture was rash raised, itchy, hot to touch, spread about 6 inches all after 24 hours of vaccination. Approximately 48 hours after entire arm felt as if it the bone was broken. Along with the above I also experienced bone/ muscle aches, chills, headache and a fever of 102.  Currently on day 4 post vaccination arm is sore, itchy, warm to touch, raised rash on arm.
Tachycardia high heart rate alert triggered on Apple Watch at rest  103-109 Sep 27 at 1:29 PM 103-111 Sep 27 at 12:07 PM 101-106 Sep 27 at 11:54 AM 100-109 Sep 27 at 10:34 AM
Redness at the injection site; Swelling at the injection site; A spontaneous report  was received from a Consumer concerning a female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced redness at the injection site and swelling at the injection site.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On unknown date, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot batch: UNKNOWN) for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced the events Redness at the injection site (injection site erythema) and Swelling at the injection site (injection site swelling) that lasted 3.5 weeks.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of events was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.
10/20/08 Vaccinated at 9AM- Pain in left upper arm 4PM and continues. Shot was given top of arm at shoulder in back. Saw family doctor, neurologist 12/08. Appt 1/13 with orthopedic Dr. Pain still in left arm and into shoulder cap. Condition is on going.
3rd-5th day after headaches; 2-3rd day:fatigue;  12th day noticed  two red patches around injection site; itching; mild soreness; tenderness
Heart palpitations. I went to me doctor and she referred me to cardiology. They did an Ultrasound on my heart but I still have to do an event monitor. No treatment. If I'm tired or don't feel good, then I notice the heart palpitations more.
On the 9th day of receiving the vaccine I developed redness, swelling  near the injection spot.  The redness is about 3inches by 2 inches. It is a little itchy.
Sensation of a swollen throat, itchiness in the throat and a hoarse voice. Slight dyspnea. To ER: IV-SOLU-MEDROL 125 mg; ZYRTEC 10 mg PO; Rx given for: Prednisone and ZYRTEC. In ER 1 hr for observation following tx.
No adverse effects were reported.; Patient was administered improperly stored VARIVAX; Information has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, previously drug reactions, allergies, concurrent conditions and concomitant medication were not reported.      On 06-JUN-2019, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) lot number R035222 with expiration date in 04-DEC-2020 (strength, anatomical location, dose and route of administration were not provided) for prophylaxis, that was reconstituted with sterile diluent (DILUENT MRK) (strength, dose, lot number, expiration date and route of administration were not provided) (it was not reported if the sterile diluent (DILUENT MRK) used had an excursion).   The varicella virus vaccine live (oka/merck) (VARIVAX) was stored at a temperature range of -9 degrees Celsius (°C) to 8°C (-3°C), for the time frame of 3 hours and 39 minutes. There was no previous temperature excursion and the call was because of a data logger.   No adverse effects were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA008695: US-009507513-1906USA008644: US-009507513-1906USA008643: US-009507513-1906USA008662: US-009507513-1906USA008721: US-009507513-1906USA008723: US-009507513-1906USA008724: US-009507513-1906USA008725:
fatigue, malaise, nausea & dizziness p/split dose of vax; poss past hx of reaction so was given 0.2cc 1st wk then 0.3cc following wk; 14SEp92 f/u recvd VAERS form; still listed as not recoverd;
Runny nose, sinus congestion, and headaches that evening after second vaccination. Mostly resolved by next morning.
This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a male patient who received SHINGRIX for prophylaxis. On 29th January 2019, the patient received SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced injection site pain, injection site erythema, injection site warmth and tiredness. On an unknown date, the outcome of the injection site pain, injection site erythema, injection site warmth and tiredness were unknown. It was unknown if the reporter considered the injection site pain, injection site erythema, injection site warmth and tiredness to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient had the SHINGRIX shot this past Tuesday afternoon, and experienced a large red spot under the shot now, it was warm and it was sore to the touch. The patient also felt a little bit more tired than usual. The patient was asking if this was natural or he should be concerned about this.
I woke at 2:15AM with uncontrollable spasms across entire body. It was worst in torso and both arms. I took 2 Advil at 2:30AM and by 3:00AM I was asleep.
Patient received the flu shot. Has gotten it every year and has experienced no issues. Patient asked for a copy of the vaccine, went to go receive it from the printer and patient passed out and fell to the ground. He regained consciousness within seconds. Patient was okay with no injury or bruising. checked blood pressure and it was within range: 126/72 with a heart rate of 79. Patient drank some water and said he was feeling much better,